The scope of this report is limited to evaluating drug stability with respect to spaceflight. The effects of spaceflight on drug pharmacokinetics (PK) or drug pharmacodynamics (PD) are not addressed in this report: these topics will be reviewed in future reports. This is the first report of the available evidence pertaining to the chemical and physical stability of drugs in the context of drug impurity, drug repackaging, and exposure to ionizing space radiation. Previous studies are discussed within this report and, where possible, the data are interpreted and contextualized with regards to drug stability.


    Access

    Access via TIB

    Check availability in my library


    Export, share and cite



    Title :

    Evidence Report: Risk of Ineffective or Toxic Medication During Long-Duration Exploration Spaceflight


    Contributors:

    Publication date :

    2023-12-20


    Type of media :

    Miscellaneous


    Type of material :

    No indication


    Language :

    English




    Future Improvements to Impact for Long Duration Exploration Spaceflight

    E Stratton / J G Steller / D Levin et al. | NTRS


    Plasma Cytokine Levels During Long-Duration Spaceflight

    Crucian, Brian E. / Zwart, Sara R. / Quiriarte, Heather A. et al. | NTRS | 2011


    Submacular Choroid Thickness Increases During Long-Duration Spaceflight

    Laurie, Steven S. / Macias, Brandon R. / Ferguson, Connor R. et al. | NTRS | 2018


    Assessment of Hematologic Parameters During Long Duration Spaceflight

    Kunz H. / Quiriarte H. / Ploutz-Snyder R. et al. | NTIS | 2016


    Personal growth following long-duration spaceflight

    Suedfeld, Peter | Online Contents | 2012